ScholarIQanswers from OpenAlex
Florida Hospital Cancer Institute
InstitutionResearch output, impact & collaborations
Florida Hospital Cancer Institute is a institution indexed in ScholarIQ from OpenAlex.
What is known about Florida Hospital Cancer Institute?
ScholarIQrecord summary
Florida Hospital Cancer Institute is a research organisation in Orlando, US. OpenAlex records 1,304 works and 312,417 citations for it. 243 researchers list it as their most recent affiliation.
How many works does Florida Hospital Cancer Institute have?
ScholarIQindexed works
Florida Hospital Cancer Institute has 1,304 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Florida Hospital Cancer Institute have?
ScholarIQcitation count
Florida Hospital Cancer Institute has 312,417 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Florida Hospital Cancer Institute?
ScholarIQresearcher count
Florida Hospital Cancer Institute has 243 researchers in the ScholarIQ index.
What is the average h-index at Florida Hospital Cancer Institute?
ScholarIQavg h-index
Florida Hospital Cancer Institute has an average h-index of 84 in OpenAlex.
What is the ROR of Florida Hospital Cancer Institute?
ScholarIQror
The ROR for Florida Hospital Cancer Institute is on the source record.
What is the OpenAlex record for Florida Hospital Cancer Institute?
ScholarIQopenalex
The OpenAlex for Florida Hospital Cancer Institute is on the source record.
Who are the most-cited researchers behind Florida Hospital Cancer Institute?
ScholarIQtop researchers by citations
What are the most-cited papers on Florida Hospital Cancer Institute?
ScholarIQmost cited works
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
David P. Carbone, Martin Reck, Luis Paz‐Ares, Ben Creelan, Leora Horn, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, John Wrangle, Delvys Rodríguez‐Abreu, Hossein Borghaei, George R. Blumenschein, Liza C. Villaruz, Libor Havel, Jana Krejčí, Jesus Corral Jaime, Han Chang, William J. Geese, Prabhu Bhagavatheeswaran, Allen C. Chen, Mark A. Socinski
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate, Ignacio I. Wistuba, Marileila Varella‐Garcia, Wilbur A. Franklin, Samuel L. Aronson, Pei-Fang Su, Yu Shyr, D. Ross Camidge, Lecia V. Sequist, Bonnie S. Glisson, Fadlo R. Khuri, Edward B. Garon, William Pao, Charles M. Rudin, Joan H. Schiller, Eric B. Haura, Mark A. Socinski, Keisuke Shirai, Heidi Chen, Giuseppe Giaccone, Marc Ladanyi, Kelly Kugler, John D. Minna, Paul A. Bunn
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial
Alice T. Shaw, Leena Gandhi, Shirish M. Gadgeel, Gregory J. Riely, Jeremy Cetnar, Howard West, D. Ross Camidge, Mark A. Socinski, Alberto Chiappori, Tarek Mekhail, Bo H. Chao, Hossein Borghaei, Kathryn A. Gold, Ali Zeaiter, Walter Bordogna, Bogdana Balas, Óscar Puig, Volkmar Henschel, Sai‐Hong Ignatius Ou
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski
How much of the research on Florida Hospital Cancer Institute is open access?
ScholarIQopen access share
78%OPEN ACCESS